Aerosolized CBD Liposomes for the treatment of Asthma and other pulmonary inflammatory disorders
OwnerMatthew Halpert, John Hartenbachinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the new compounds and improved treatment regimens that are effective in treating patients and minimizing the negative side effects previously associated with pulmonary care and treatment. Specifically, liposomal cannabinoids with or without other known treatments are used to provide a more effective and safer treatment for Asthma and/or pulmonary inflammation disorders or conditions in a diverse population.
Claims5
A method for treating pulmonary inflammation disorders or conditions comprising a therapeutically effective amount of one or more endocannabinoids in a liposomal encapsulation.
A cannabinoid liposome formulation comprising:
- a liposome carrier and one or more cannabinoids in a formulation.
Dependencies are inferred from the claim text.